FDA turns down chronic fatigue drug
from MedPage Today
The FDA will require a new clinical trial of rintatolimod as well as additional types of data before it will approve the drug for chronic fatigue syndrome, its manufacturer said. Hemispherx Inc. said it had received a "complete response letter" from the FDA, indicating that the company "should conduct at least one additional clinical trial, complete various nonclinical studies and perform a number of data analyses."
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063